Novo Nordisk A/S (NYSE:NVO) Coverage Initiated by Analysts at Sanford C. Bernstein

Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S (NYSE:NVO) in a research report sent to investors on Wednesday, MarketBeat reports. The firm issued an outperform rating and a $175.00 target price on the stock.

A number of other equities analysts have also commented on the stock. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research report on Tuesday, March 10th. Finally, Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $37.48 on Wednesday. The firm has a market cap of $167.33 billion, a price-to-earnings ratio of 10.80 and a beta of 0.73. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $81.44. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a 50-day moving average of $49.07 and a 200-day moving average of $51.39.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in NVO. Martin Capital Partners LLC boosted its position in Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after buying an additional 41,129 shares during the last quarter. Smith Chas P & Associates PA Cpas boosted its holdings in Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after buying an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC grew its holdings in Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after purchasing an additional 37,453 shares during the period. Markel Group Inc. grew its holdings in shares of Novo Nordisk A/S by 4.9% in the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after buying an additional 110,061 shares during the period. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Novo Nordisk A/S in the third quarter valued at about $1,294,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Sanford C. Bernstein initiated coverage with an “outperform” rating and a $175 price target — a highly bullish call that signals large upside expectations if Novo executes and GLP‑1 demand holds.
• Positive Sentiment: New research finds stopping GLP‑1 therapy raises risks of heart attack, stroke and death in Type 2 diabetes patients, which supports the clinical value and stickiness of Novo’s GLP‑1 franchise (Ozempic/Wegovy). Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Positive Sentiment: Commercial distribution boost: Novo partnered with Hims & Hers to expand access to its GLP‑1 drugs, potentially widening patient reach and prescription starts. Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
• Neutral Sentiment: Market commentaries debate valuation after a large multi‑quarter selloff — some investors see a buying opportunity while others view persistent risks as justification for the decline. Is Novo Nordisk (NYSE:NVO) Starting To Look Interesting After A 52% One Year Slide?
• Neutral Sentiment: Several media/analyst pieces are keeping the stock in investor focus — mixed takes from bullish buy-the-dip articles to pieces noting increased attention. Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Competitive risk: Structure Therapeutics reported oral GLP‑1 data showing weight‑loss results comparable to Wegovy, highlighting a material threat from oral small‑molecule competitors that could pressure pricing and volume. Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
• Negative Sentiment: Legal risk: The Portnoy Law Firm has opened an investigation into possible securities fraud and may pursue a class action, introducing potential litigation exposure and short‑term headline risk. Novo Nordisk A/S Investigated by the Portnoy Law Firm
• Negative Sentiment: Sector growth/price pressure concerns: HSBC flagged lower-than-consensus obesity market size and pricing risks that could cap long‑term revenue upside for major GLP‑1 players. HSBC Downgrades Eli Lilly, Cuts PT to $850, Flags Obesity Market Risks

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.